Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial

Folia Biologica

Volumn 49, Issue 2, 2003, Pages 69-73

  Doehn, Christian Deohn ^a   Richter, A ^b   Lehmacher, W ^c   Jocham, D ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Klinikum St Georg   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR CELL VACCINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE ORGANIZATION; HUMAN; KIDNEY CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NEPHRECTOMY; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STANDARDIZATION; SURVIVAL TIME; TUMOR GROWTH; VACCINATION;

EID: 0038634888     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Basting, R., Corvin, S., Handel, D., Hinke, A., Schmidt, D. (1999) Adjuvant immunotherapy in renal cell carcinoma - comparison of interferon alpha treatment with untreated control. Anticancer Res. 19, 1545-1548.
2. Boon, T., Cerottini, J. C., Van den Eynde, B., Van der Bruggen, P., Van Pel, A. (1994) Tumor antigens recognized by T lymphocytes. Rev. Immunol. Ann. 12, 337-365.
3. Dal Bianco, M., Arbitani, W., Bassi, P. F., Pescatori, E., Pagano, F. (1988) Prognostic factors in renal cell carcinoma. Eur. Urol. 115, 73-76.
4. Dillman, R. O., Nayak, S. K., Beutel, L. (1993) Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J. Immunother 14, 65-69.
5. Dinney, C. P., Awad, S. A., Gajewski, J. B., Belitsky, P., Lannon, S. G., Mack, F. G., Millard, O. H. (1992) Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology 39, 122-129.
6. Figlin, R. A. (1999) Renal cell carcinoma: management of advanced disease. J. Urol. 161, 381-387.
7. Finney, R. (1973) The value of radiotherapy in the treatment of hypernephroma - a clinical trial. Br. J. Urol. 45, 258-269.
8. Fischer, C. C., Wächter, W. C., Fuentecilla Perez, E., Miller, J., Weidner, W., Dudeck, J. (1997) Urologic tumors in Germany. Urologe A 36, 143-150.
9. Galligioni, E., Quaia, M., Merlo, A., Carbone, A., Spada, A., Favaro, D., Santarosa, M., Sacco, C., Talamini, R. (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77, 2560-2566.
10. Gansbacher, B., Zeier, K., Daniels, B., Cronin, K., Bennerji, R., Gilboa, E. (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
11. Giuliani, L., Gilberti, C., Martorana, G., Rovida, S. (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J. Urol. 143, 468-474.
12. Guinan, P. D., Vogelzang, N. J., Fremgen, A. M., Chmiel, J. S., Sylvester, J. L., Sener, S. F., Imperato, J. P. (1995) Renal cell carcinoma: tumor size, stage and survival. J. Urol. 153, 901-903.
13. Goldschmidt, A. J. W., Hockertz, S. W., Repmann, R., Richter, A., Ulbrich, C., Großmann, A. (1998) Adjuvant therapy of renal cell carcinoma (RCC) with a pure-cell-lysate autologous tumor vaccine (aTm): a 3-year-follow-up-analysis. Proc. Am. Ass. Cancer Res. 39, 367.
14. Hermanek, P., Schrott, K. M. (1990) Evaluation of the new tumor, nodes and metastases classification of renal carcinoma. J. Urol. 144, 238-242.
15. Jeon, S. H., Chang, S. G., Kim, J. I. (1999) The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in factors in pT3N0M0 renal cell carcinoma. Anticancer Res. 19, 5593-5597.
16. Kjaer, M., Frederiksen, P. L., Engelholm, S. A. (1987) Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study group. Int. J. Radiat. Oncol. Biol. Physiol. 13, 665-672.
17. Kriegmair, M., Oberneder, R. (1995) Tumor cell vaccination for treatment of renal cell carcinoma. Urologe A 34, 204-207.
18. Levy, D. A., Slaton, J. W., Swanson, D. A., Dinney, C. P. (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159, 1163-1167.
19. Makarewicz, R., Zarzycka, M., Kulinska, G., Windorbska, W. (1998) The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 45, 380-383.
20. McNichols, D. W., Segura, J. W., DeWeerd, J. H. (1981) Renal cell carcinoma: long-term survival and late recurrence. J. Urol. 126, 17-23.
21. Migliari, R., Muscas, G., Solinas, A., Melis, M., Ionta, M. T., Massidda, B., Usai, E. (1995) Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? J. Chemother. 7, 240-245.
22. Motzer, R. J., Bander, N. H., Nanus, D. M. (1996) Renal-cell carcinoma. New Engl. J. Med. 335, 865-875.
23. Motzer, R. J., Russo, P. (2000) Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417.
24. Pizzocaro, G., Piva, L., Colavita, M., Ferri, S., Artusi, R., Boracchi, P., Parmiani, G., Marubini, E. (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 19, 425-431.
25. Pomer, S., Thiele, R., Staehler, G., Drehmer, L., Lohrke, H., Schirrmacher, V. (1995) Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization. Urologe A 34, 215-220.
26. Rabinovitch, R. A., Zelefsky, M. J., Gaynor, J. J., Fuks, Z. (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjunct local and systemic therapy. J. Clin. Oncol. 12, 206-212.
27. Rammensee, H. G. (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7, 85-96.
28. Repmann, R., Wagner, S., Richter, A. (1997) Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res. 17, 2879-2882.
29. Robson, C. J., Churchill, B. M., Anderson, W. (1969) The results of radical nephrectomy for renal cell carcinoma. J. Urol. 101, 297-301.
30. Sandock, D. S., Seftel, A. D., Resnick, M. I. (1995) A new protocol for the followup of renal cell carcinoma based on pathological stage. J. Urol. 154, 28-31.
31. Stevanovic, S., Pomer, S., Rammensee, H. G. (1995) Surface antigens in renal cell carcinoma: presentation of MHC I-restricted self peptides. Akt. Urol. 26, 45-46.
32. Störkel, S., Thoenes, W., Jacobi, G. H., Lippold, R. (1989) Prognostic parameters in renal cell carcinoma - a new approach. Eur. Urol. 16, 416-422.
33. Tsui, K. H., Shvarts, O., Smith, R. B., Figlin, R. A., deKernion, J. B., Belldegrun, A. (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J. Urol. 163, 1090-1095.
34. Wittekind, C., Wagner, G. (1997) TNM Classification of malignant tumors. 5th edition, Springer, Berlin/Heidelberg. http://www.seer.cancer.gov
35. Yagoda, A., Bassam, A. R., Petrylak, D. (1995) Chemotherapy for advanced renal cell carcinoma 1983-1993. Semin. Oncol. 22, 42-60.